Bloom Burton & Co. Upgrades Aurinia Pharmaceuticals (AUPH) to Buy (1)
Bloom Burton & Co. analyst David Martin upgraded Aurinia Pharmaceuticals (NASDAQ: AUPH) from Hold (3) to Buy (1) with a price target of $21.00.
For an analyst ratings summary and ratings history on Aurinia Pharmaceuticals click here. For more ratings news on Aurinia Pharmaceuticals click here.
Shares of Aurinia Pharmaceuticals closed at $16.17 yesterday.